Johnson & Johnson JNJ

$266.30 +2.49 (0.94%)

Valuation

Market cap
635,072,512,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
25.13
Forward PE
24.07
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,777,400
Avg volume
6,979,752
Day's range
$264.97 – $272.36
Shares out
2,407,310,000
Stochastic %K
75%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

KingTrades09 Oct 27, 1:58 PM 1 replies
KingTrades09 Oct 27, 1:55 PM
$IBM $WMT $JNJ Bullish on all 3.. charts explosive. Will share
0 replies
picckles Oct 27, 1:43 PM
$JNJ closed +2.51% in 2 days. Alert bought at $252.93 (Oct 5), sold at $259.27 (Oct 7). Sell rule #1: when it pops, I sell. #2: stuck 20 trading days → out at break-even. #3: closes 13% down → sell the first bounce at −10%. Every alert, losses included: picckles.com/track-record
0 replies
Fliptax Oct 27, 12:27 PM
$PFE https://finance.yahoo.com/healthcare/articles/pfizer-elrexfio-outperforms-standard-regimens-104500090.html $JNJ $MRNA $LLY
0 replies
focafoca99 Oct 27, 12:11 PM
$JNJ launches its Enterprise Business Review for investors on Dec 8, 2026. https://www.rapidticker.com/news/jnj-johnson-amp-johnson-to-host-728a22
0 replies
DoubleUpwithChuck Oct 27, 5:19 AM
$JNJ $GSK $PFE $ABBV I think our buyer will be pharma. Quantum companies are looking at them like ripe customers. They need to buy Zapata now
1 replies
whymystockmoved Oct 27, 12:41 AM
$ORIC fell about 32% to $8.96 on Monday; we found no ORIC release or filing that day. Over the weekend, Johnson & Johnson reported early results for JNJ-6143, a pill for the same advanced prostate cancer that ORIC's lead drug, rinzimetostat, targets. A Leerink analyst said the data raise the competitive threat to rinzimetostat. The catch: the two drugs haven't been compared in the same trial, and ORIC has its own Phase 3 under way. Full breakdown: https://whymystockmoved.com/stocks/oric/2026-10-26-why-oric-pharmaceuticals-stock-fell/ $JNJ
0 replies
TearsForFear Oct 26, 7:47 PM
$IBRX @AztecPyramid I’m thinking e’s will be just fine. $JNJ should be worried Hugely about anktiva in bcg naive treatment. Anktiva First mover Advantage will put jnj in dog house for
0 replies